Table 1.
Correlation of the expression of FABP1 in gastric cancer with clinicopathologic features.
| Characteristics | No. of patients | FABP1 | P value | |
|---|---|---|---|---|
| Low expression, n (%) | High expression, n (%) | |||
| Overall | 94 | 35 (37.2) | 59 (62.8) | |
| Age | 0.110 | |||
| <60 years, n (%) | 25 (26.6) | 19 (76.0) | 6 (24.0) | |
| ≥60 years, n (%) | 69 (73.4) | 40 (58.0) | 29 (42.0) | |
| Gender | 0.385 | |||
| Female | 59 (62.8) | 39 (66.1) | 20 (33.9) | |
| Male | 35 (37.2) | 20 (57.1) | 15 (42.9) | |
| Tumor size | 0.565 | |||
| <5.0 cm | 33 (35.1) | 22 (66.7) | 11 (33.3) | |
| ≥5.0 cm | 61 (64.9) | 37 (60.7) | 24 (39.3) | |
| Primary tumor location | 0.770 | |||
| Gastric cardial + body | 60 (63.8) | 37 (61.7) | 23 (38.3) | |
| Gastric antral | 34 (36.2) | 22 (64.7) | 12 (35.3) | |
| Pathological type | 0.534 | |||
| Adenocarcinoma | 78 (83.0) | 50 (64.1) | 28 (35.9) | |
| Mucinous + signet-ring cell carcinoma | 16 (17.0) | 9 (56.3) | 7 (43.7) | |
| Lymph node metastasis | 0.684 | |||
| Negative | 72 (76.6) | 46 (63.9) | 26 (36) | |
| Positive | 22 (23.4) | 13 (59.1) | 9 (40.9) | |
| TNM stage | 0.370 | |||
| I + II | 35 (37.2) | 24 (68.6) | 11 (31.4) | |
| III + IV | 59 (62.8) | 35 (59.3) | 24 (40.7) | |
| HER2 | 0.668 | |||
| Positive | 6 (6.4) | 5 (83.3) | 1 (16.7) | |
| Negative | 88 (93.6) | 54 (61.4) | 34 (38.6) | |